Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2007
10/18/2007US20070243182 Use of Carboxypeptidease G for Combating Antifolate Toxicity
10/18/2007US20070243181 Irak1c Splice Variant And Its Use
10/18/2007US20070243180 Composition Containing Reduced Coenzyme Q
10/18/2007US20070243177 Methods and compositions for treatment of diabetes and related disorders
10/18/2007US20070243166 Hepatitis C Inhibitor Compounds
10/18/2007US20070243161 Epigenetic modification of the loci for CAMTA1 and/or FOXP3 as a marker for cancer treatment
10/18/2007US20070243156 Synthesis and utilization of peptide mimetics in drug discovery and medicine
10/18/2007US20070243147 Skin and/or Hair Composition Containing Compounds for Increasing The Tanning of Skin
10/18/2007US20070243140 Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
10/18/2007US20070243135 Method of treating fetal growth retardation and placental ischaemia and insufficiency
10/18/2007US20070243132 Transdermal delivery of pharmaceutical agents
10/18/2007DE69233686T2 Heteoaryl-Piperidine und Piperazine und ihre Anwendung als antipsychotisches und analgetisches Mittel Heteoaryl-piperidines and piperazines and their use as antipsychotic and analgesic agent
10/18/2007DE102007016665A1 Kosmetische, pharmazeutische und/oder dermatologische Zusammensetzungen enthaltend langkettige Fettalkohole und/oder deren Derivate Cosmetic, pharmaceutical and / or dermatological compositions comprising long chain fatty alcohols and / or derivatives thereof
10/18/2007DE102006018869A1 17alpha-substituierte 4-(3-Oxoestra-4,9-dien-11beta-yl)-benzoesäure, deren Derivate und Verfahren zu ihrer Herstellung 17alpha-substituted 4- (3-oxoestra-4,9-dien-11beta-yl) benzoic acid, their derivatives and process for their preparation
10/18/2007DE102006017831A1 Producing transgenic brassica plants with increased glucosinolate synthesis comprises causing overexpression of the gene coding for transcription factor MYB51
10/18/2007DE102006017827A1 Neue kristalline Verbindungen New crystalline compounds
10/18/2007DE102006016990A1 Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen Use of baclofen and baclofen derivatives for the withdrawal and / or substitution treatment when dependent on GHB and / or GHB analogs
10/18/2007CA2853611A1 High delivery rates for lipid based drug formulations, and methods of treatment thereof
10/18/2007CA2683064A1 Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions
10/18/2007CA2661789A1 Modified .alpha.-galactosyl ceramides for staining and stimulating natural killer t cells
10/18/2007CA2659767A1 Anti-inflammatory agent and cancer-preventive agent comprising canolol or prodrug thereof and pharmaceutical, cosmetic and food comprising the same
10/18/2007CA2654218A1 Process for the preparation of pure irbesartan
10/18/2007CA2652307A1 Compositions and methods for modulating gated ion channels
10/18/2007CA2652109A1 Compositions and methods for modulating gated ion channels
10/18/2007CA2651898A1 Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
10/18/2007CA2651159A1 Pharmaceutical compositions and uses thereof
10/18/2007CA2649364A1 The homeobox transcription factor bsx and uses thereof for treating diseases, in particular obesity
10/18/2007CA2649214A1 Condensed imidazole derivatives as aromatase inhibitors
10/18/2007CA2649213A1 Imidazo compounds
10/18/2007CA2649210A1 Spiro-imidazo compounds
10/18/2007CA2649194A1 Pharmaceutical composition that comprises an analgesic and vitamins
10/18/2007CA2649090A1 Intramuscular antiviral treatments
10/18/2007CA2649000A1 N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
10/18/2007CA2648980A1 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases
10/18/2007CA2648943A1 Mazindol combination in the treatment of attention deficit/hyperactivity
10/18/2007CA2648923A1 Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
10/18/2007CA2648914A1 Pyridyloxadiazole substituted compounds and compositions
10/18/2007CA2648742A1 Compositions including relatively water insoluble/unwettable drugs and methods for using same
10/18/2007CA2648719A1 Modulators of atp-binding cassette transporters
10/18/2007CA2648718A1 Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
10/18/2007CA2648687A1 Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists
10/18/2007CA2648668A1 Synthesis of tetracyclines and analogues thereof
10/18/2007CA2648653A1 Fat accumulation inhibitor
10/18/2007CA2648613A1 Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders
10/18/2007CA2648604A1 Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
10/18/2007CA2648585A1 Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
10/18/2007CA2648479A1 Implants for the treatment of dopamine associated states
10/18/2007CA2648407A1 Compositions and methods for treating polycystic kidney disease
10/18/2007CA2648335A1 Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
10/18/2007CA2648324A1 2-methylene-1.alpha.,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
10/18/2007CA2648323A1 Substituted ring fused azines and their use in cancer therapy
10/18/2007CA2648303A1 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists
10/18/2007CA2648287A1 Spirocyclic heterocyclic derivatives and methods of their use
10/18/2007CA2648281A1 Co-administration of adenosine a1 receptor antagonists and anticonvulsants
10/18/2007CA2648193A1 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof
10/18/2007CA2648172A1 Drugs and food products for hypophosphoric normo-, hyper- and hypoproteic diets, and hypophosphoric beverages
10/18/2007CA2648170A1 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
10/18/2007CA2648168A1 Heterocyclic gaba alpha subtype selective receptor modulators
10/18/2007CA2648115A1 Ocular allergy treatments
10/18/2007CA2648074A1 11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
10/18/2007CA2648055A1 Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
10/18/2007CA2648042A1 Opiopathies
10/18/2007CA2647907A1 Use of tm-601 for the diagnosis and treatment of tumors
10/18/2007CA2647903A1 Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
10/18/2007CA2647803A1 Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
10/18/2007CA2647502A1 Onco-tool compositions and methods of use for detecting and treating tumors
10/18/2007CA2647448A1 Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
10/18/2007CA2647440A1 5-amido-2-carboxamide indoles
10/18/2007CA2647434A1 Thiazolyldihydroindazoles
10/18/2007CA2647381A1 Microemulsifiable formulations comprising azoxystrobin and propiconazole
10/18/2007CA2647295A1 Thiazolyldihydroindazoles
10/18/2007CA2647292A1 Thiazolyldihydrocyclopentapyrazoles for use as pi3-kinase inhibitors
10/18/2007CA2647258A1 Combination treatment of metabolic disorders
10/18/2007CA2647073A1 Drug microparticles
10/18/2007CA2646917A1 Novel sulfonamide compounds
10/18/2007CA2646899A1 Use of compositions containing kappa-opioid receptor antagonists for the treatment of dissociative disorders
10/18/2007CA2646676A1 Heterocyclic gpcr agonists
10/18/2007CA2646578A1 Novel formulations
10/18/2007CA2646571A1 Thiazolyl-dihydroquinazolines
10/18/2007CA2646250A1 Use of rasagiline for the treatment of restless legs syndrome
10/18/2007CA2645547A1 Biguanide-containing liposomes
10/18/2007CA2645260A1 Renin inhibitors for the treatment of hypertension
10/18/2007CA2645171A1 Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
10/18/2007CA2644951A1 Chromen-2-one derivatives
10/18/2007CA2644913A1 Methods for prevention and treatment of conditions arising from local estrogen deficiency
10/18/2007CA2644910A1 Indazole compounds
10/18/2007CA2644841A1 Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
10/18/2007CA2644783A1 Selective hydroxamate based mmp inhibitors
10/18/2007CA2644721A1 Use of inhibitors of jun n-terminal kinases to treat glaucoma
10/18/2007CA2644391A1 Organic compounds
10/18/2007CA2643863A1 Compounds which modulate the cb2 receptor
10/18/2007CA2643659A1 Organic compounds
10/18/2007CA2643633A1 The use of an antibody directed against beta amyloid peptide for the treatment of alzheimer's disease
10/18/2007CA2643011A1 Quinolones useful as inducible nitric oxide synthase inhibitors
10/18/2007CA2642757A1 Solid dispersion of poorly soluble drugs in graft copolymers
10/18/2007CA2640463A1 Preparation of gemcitabine
10/18/2007CA2635310A1 Anthracenedione compounds
10/17/2007EP1845405A1 Liquid agent composition for contact lens
10/17/2007EP1845163A2 Adeno-associated virus serotype l nucleic acid sequences, vetors and host cells containing same
10/17/2007EP1845102A1 Novel pyrimidine nucleoside compound or its salt
1 ... 3541 3542 3543 3544 3545 3546 3547 3548 3549 3550 3551 3552 3553 3554 3555 3556 3557 3558 3559 3560 3561 ... 7860